Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Gamida-Cell is a biopharmaceutical company developing stem cell (SC) therapeutic products applicable to cancer and
autoimmune diseases, as well as future regenerative cell-based medicines, based on its proprietary SC and progenitor
cell (PC) expansion technology. The company was founded in 1998, based on technology licensed from Hadassah
University Medical Center, Jerusalem, Israel. Gamida-Cell aims to lead the field of SC therapeutics and regenerative
medicine applications.